Audit: QRS - Green Tea Extract for Health & Longevity
Audit conducted on 21/09/2026 03:18 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every element traces to the ER: protocol cells to Therapeutic Protocol (ER 383-391), benefit/risk items to the ER tier headings, gates to Key Interactions & Contraindications (ER 323-359), markers to the ER monitoring table (ER 476-484), qualitative items to ER 488-492. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious ER phrasing is carried through, e.g. ER “should expect to gain very little” appears as “negligible where they are already healthy” in [at_a_glance]. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found. The TKI/antifibrotic gate keeps the ER qualifier “during active therapy” (ER 333). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Benefit-Modifying and Risk-Modifying Factors are not surfaced as gates or side effects; contraindications come from the ER avoid-list (ER 351-359) plus the two bullets the ER itself calls contraindications. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, study citations, expert names, NCT identifiers or brand names. The only proper name, Garcinia cambogia, is in the ER at 345. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Tone matches the ER: measured, quantitative, explicit about the liver signal and the commercial funding caveat. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven while remaining accessible; targets and thresholds are given without hedging. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Reads as a distillation of evidence, not as instruction from a clinician. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives or clinical directives; the footer disclaimer is unmodified template text. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Information is presented, e.g. “Capsules taken with a meal”, “Splitting with breakfast and the evening meal is standard”. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout; technical terms are the ER’s own and are standard cardiometabolic vocabulary. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Benefits and risks are reduced to ER tier headings; gate items are drug classes with example lists only. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”, “your” or “yourself” in the file. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes a reader already weighing whether to run the protocol and monitor it. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol, dose separation, four-hour/two-hour spacing and a seven-marker monitoring panel all presuppose a reader willing to take on effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not pitched at the general population; the framing is optimisation and risk management. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | [at_a_glance] explicitly flags that gains are “negligible where they are already healthy”, the key signal difference for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” phrasing anywhere; the page title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Formal register throughout, including “oral medications” in the lede rather than any lay term for route of administration. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: * Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” * Gate headings: “Contraindications”, “Key Interactions” * Tier labels: “High”, “Medium”, “Low”, “Speculative” * Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings verified against the template: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”, “Contraindications”, “Key Interactions”, the four tier labels, and “Marker”/”Target”/”Why”. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variables are present; the repeatable marker_#* and qualitative_item# rows are expanded to 7 and 5 instances respectively. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A normalised diff against [qrs_template] shows the only structural differences are the expected repeated monitoring rows and qualitative list items. The three website=”…” spans are byte-identical to the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section feeding the QRS is empty, so no empty-state phrasing is required. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels are the ER bold labels verbatim: “Standard daily dose”, “Always with food”, “Split versus single dose” (ER 383, 385, 387). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names reproduce the ER biomarker column verbatim; no invented labels. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji present; the ER’s tier squares and the ⚠️ Conflicted markers are stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every field is condensed to the floor the rest of the checklist allows: benefits and risks are ER headings only, gate items carry no rationale, [at_a_glance] is at its 60-word ceiling. The residual length is driven by content that 8.2, 9.2, 12.2, 13.2, 14.2 and 15.2 require to be carried in full. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The comment opens on line 2, directly after “<!doctype html>” on line 1, and precedes all other content. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML is delimited by “—” on lines 3 and 13; the preceding descriptive text is outside the block. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | It is an HTML comment and no element on the sheet surfaces its values. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed and unquoted except duration: “00:03”, which contains a colon and therefore requires quoting. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | “er_filename: green_tea_extract_2026-0921-0002_Opus_ER.md” (line 4). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | “qrs_prompt_version: 26.9.11” matches the version badge of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | “qrs_creation_date: 2026-0921-0251” is in YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | “qrs_creator_ai_nickname: Opus” (line 7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | “qrs_creator_ai_fullname: Opus 5” (line 8). |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no trailing qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | “qrs_filename: green_tea_extract_2026-0921-0002_Opus_QRS.html” matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: no stray whitespace and no unnecessary quoting on any key. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “ |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | [header_topic] is “Green Tea Extract for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | qrs_creation_date 2026-0921 renders as “09/21/2026”. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | [header_subline_model] is “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | No badge, version stamp, audit date or variant marker; the ER “Also known as” line is correctly omitted. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses all three Conclusion paragraphs: what the product is, the size and conditionality of the benefit, and the two distinctive harms. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words, verified by word count. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion sentence (ER 512, 514). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “low-density lipoprotein”, “hepatotoxicity” and similar terms are replaced by “cholesterol” and “liver inflammation”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, relative risks or statistical results; magnitudes are given only as “small, consistent”. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All items trace to the ER Key Interactions & Contraindications section (ER 323-359). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All seven ER avoid-list populations (ER 353-359) are present, plus the proteasome-inhibitor and TKI/antifibrotic bullets that the ER itself designates contraindications (ER 331, 333). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the [stop_items] span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No trailing rationale and no dash-delimited clauses; the ER’s parenthetical glosses for AST and for the boronic-acid mechanism are stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Thresholds and windows retained: “above 2.5 times the upper reference limit”, “ferritin below 30 ng/mL until iron status is corrected”, “more than 14 standard drinks weekly”, “during active therapy”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER Key Interactions & Contraindications bullets use no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does name populations that should avoid the intervention. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty (8 items), so no empty-state HTML comment is required. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All items trace to the ER Key Interactions & Contraindications section. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All 13 ER interaction bullets are represented except the two carried as contraindications, giving 11 items in ER order. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eleven <li> elements inside the [caution_items] span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No mechanistic rationale, countermeasures or citations; the ER’s “Four-hour dose separation” and similar trailing sentences are dropped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists are preserved for every class, and the “for caffeinated extracts only” qualifier is kept on the decongestant item. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER Key Interactions & Contraindications bullets use no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER does name interactions that change how the intervention is used. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty (11 items), so no empty-state HTML comment is required. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from the ER Therapeutic Protocol section (ER 381-407). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, food requirement and dose splitting are the three actionable levers; the remaining ER bullets are background, competing approaches or non-actionable genotype notes. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol supplies more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine fields carry ER-derived content; action_3_sub correctly folds in the ER “Best time of day” constraint. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Blood pressure, lipids and body composition are the three time courses the ER gives (ER 444). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered blood pressure, lipids, body composition, matching the ER’s own ordering of the High-tier benefits. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine fields populated; time_1_sub carries the ER phrase “Nothing meaningful is measurable in days” verbatim. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER Practical Considerations provides time-to-effect data, so the row is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from the ER Expected Benefits section (ER 145-225). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four variables are present and populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are the ER sub-headings only; no magnitudes, confidence intervals or mechanisms. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives; “Extension of Lifespan Through Senescence and Autophagy Pathways” is reduced to “Extension of lifespan”. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers are populated in the ER Expected Benefits section. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from the ER Potential Risks & Side Effects section (ER 245-301). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four variables are present and populated. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are the ER sub-headings only; no incidence figures, odds ratios or mechanisms. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives; the ⚠️ Conflicted markers are removed. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers are populated in the ER Potential Risks & Side Effects section. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All seven ER biomarker rows are present, with names, functional ranges and rationale reproduced verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | [monitoring_cadence] carries the full ER cadence including the baseline panel, the 8-12 week and 6-month liver checks, the 12-week and annual cardiometabolic panel, and the symptom-triggered override. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers (ER 488-492) are listed verbatim. |
Issues 21/09/2026 03:18
Pass rate 100.00%. No issues found.
Issues 21/09/2026 03:09
- 12.3 — Mechanism in speculative benefit: [benefits_speculative] at line 557 carries “through senescence and autophagy pathways”, a mechanistic explanation that item 12.3 excludes from benefit items.
Fixes 21/09/2026 03:09
- 12.3 — Mechanism in speculative benefit: Trimmed [benefits_speculative] from “Extension of lifespan through senescence and autophagy pathways” to “Extension of lifespan”, removing the mechanistic trailing clause.
Issues 21/09/2026 03:04
- 2.5 — Imperative dosing instruction: [action_3_sub] (line 484) begins “Split with breakfast and the evening meal”, a bare imperative that advises the reader instead of presenting the ER’s statement that splitting into two doses with breakfast and the evening meal “is standard” (ER line 387).
Fixes 21/09/2026 03:04
- 2.5 — Imperative dosing instruction removed: [action_3_sub] changed from “Split with breakfast and the evening meal; caffeinated preparations kept to before mid-afternoon” to “Splitting with breakfast and the evening meal is standard; caffeinated preparations kept to before mid-afternoon”, matching the ER’s declarative framing.
Issues 21/09/2026 02:57
- 1.1 — At-A-Glance inverts benefit direction: The At-A-Glance span (line 435) reports “small, consistent gains in blood pressure, cholesterol, blood sugar and body fat”, whereas the ER Conclusion (line 512) says “improvements”; “gains” reads as an increase in exactly the four measures whose documented benefit is a reduction.
Fixes 21/09/2026 02:57
- 1.1 — At-A-Glance benefit direction: Changed “small, consistent gains in blood pressure, cholesterol, blood sugar and body fat” to “small, consistent improvements in …”, matching the ER Conclusion and removing the reading that those four measures increase.